Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Turing Names Eliseo Salinas President of R&D | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Turing Names Eliseo Salinas President of R&D

Former chief scientific officer for Shire Pharmaceuticals and Relmada Therapeutics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Turing Pharmaceuticals AG announced that life sciences executive and medical researcher Eliseo Oreste Salinas, MD, MSc,  has joined the company as president of research and development.

Dr. Salinas, who holds a medical degree as well as a masters in pharmacology, brings a record of significant accomplishments in the pharmaceutical industry, and extensive clinical experience in psychiatry.

Dr. Salinas has played a leadership role in numerous programs for a range of diseases and disorders, with a concentration on central nervous system conditions including depression and anxiety, schizophrenia, epilepsy, stroke, Parkinson’s, attention deficit disorder and Alzheimer’s disease. Fifteen separate drug programs under his direction led to approvals by the Food and Drug Administration and international regulatory bodies.

He arrives as Turing prepares to begin clinical trials for several of its drugs, including an innovative intranasal formulation for ketamine to treat severe depression and suicidality.

“We are pleased to welcome Eliseo Salinas to our leadership team,” said Turing founder and chairman Martin Shkreli. “Eliseo combines proven capabilities to bring important new treatments to patients and their physicians, with a deep understanding of the patient and physician communities. His appointment is another major step as we build Turing’s capabilities for the long-term, advance our existing pipeline and work to create and acquire new assets.”

Dr. Salinas joins Turing from Relmada Therapeutics, a New York-based clinical stage drug company focused primarily on pain management; he served as Relmada’s president and chief scientific officer as well as head of R&D. Previously he was executive vice president and director of R&D for Newark, CA-based Stem Cells, Inc.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics